POLITECNICO DI TORINO Repository ISTITUZIONALE

Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme

Original

Piezoelectric barium titanate nanostimulators for the treatment of glioblastoma multiforme / Marino, A.; Almici, E.; Migliorin, S.; Tapeinos, C.; Battaglini, M.; Cappello, V.; Marchetti, M.; de Vito, G.; Cicchi, R.; Pavone, F. S.; Ciofani, G. -In: JOURNAL OF COLLOID AND INTERFACE SCIENCE. - ISSN 0021-9797. - STAMPA. - 538:(2019), pp. 449-461. [10.1016/j.jcis.2018.12.014]

Availability: This version is available at: 11583/2720704 since: 2018-12-15T11:06:10Z

Publisher: Elsevier

Published DOI:10.1016/j.jcis.2018.12.014

Terms of use:

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright Elsevier postprint/Author's Accepted Manuscript

© 2019. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/.The final authenticated version is available online at: http://dx.doi.org/10.1016/j.jcis.2018.12.014

(Article begins on next page)

1 Piezoelectric Barium Titanate Nanostimulators for the Treatment

2

of Glioblastoma Multiforme

- 3 Attilio Marino^{1,†,*}, Enrico Almici^{2,†}, Simone Migliorin², Christos Tapeinos¹, Matteo Battaglini^{1,3},
- 4 Valentina Cappello⁴, Marco Marchetti^{5,6}, Giuseppe de Vito^{5,7}, Riccardo Cicchi^{5,7}, Francesco
- 5 Saverio Pavone^{5,6,7}, Gianni Ciofani^{1,2,*}
- ⁶ ¹Istituto Italiano di Tecnologia, Smart Bio-Interfaces, Viale Rinaldo Piaggio 34, 56025 Pontedera, Italy
- ²Politecnico di Torino, Department of Mechanical and Aerospace Engineering, Corso Duca degli Abruzzi
 24, 10129 Torino, Italy
- ³Scuola Superiore Sant'Anna, The Biorobotics Institute, Viale Rinaldo Piaggio 34, 56025 Pontedera, Italy
- ⁴Istituto Italiano di Tecnologia, Center for Nanotechnology Innovation, Piazza San Silvestro 12, 56127
 Pisa, Italy
- ⁵European Laboratory for Nonlinear Spectroscopy (LENS), Via Nello Carrara 1, 50019 Sesto Fiorentino,
 Italy
- ⁶Università di Firenze, Department of Physics and Astronomy, Via Giovanni Sansone 1, 50019 Sesto
 Fiorentino, Italy
- ¹⁶ ⁷National Institute of Optics, National Research Council (INO-CNR), Largo Enrico Fermi 6, 50125
- 17 Firenze, Italy
- [†]These authors contributed equally to this work
- 19 *CORRESPONDING AUTHORS:
- 20 <u>attilio.marino@iit.it; gianni.ciofani@iit.it</u>

21

23

24 ABSTRACT

25 Major obstacles to the successful treatment of gliolastoma multiforme are mostly related to the 26 acquired resistance to chemotherapy drugs and, after surgery, to the cancer recurrence in 27 correspondence of residual microscopic foci. As innovative anticancer approach, low-intensity 28 electric stimulation represents a physical treatment able to reduce multidrug resistance of cancer and to induce remarkable anti-proliferative effects by interfering with Ca²⁺ and K⁺ homeostasis 29 30 and by affecting the organization of the mitotic spindles. However, to preserve the proliferation 31 and behavior of healthy cells, it is utterly important to direct the electric stimuli only to 32 malignant cells. In this work, we propose a nanotechnological approach based on ultrasound-33 sensitive piezoelectric nanoparticles to remotely deliver electric stimulations to glioblastoma 34 cells. Barium titanate nanoparticles (BTNPs) have been functionalized with an antibody against 35 the transferrin receptor (TfR) in order to obtain the dual targeting of blood-brain barrier and of 36 glioblastoma cells. The remote ultrasound-mediated piezo-stimulation allowed to significantly 37 reduce *in vitro* the proliferation of glioblastoma cells and, when combined with a sub-toxic 38 concentration of temozolomide, induced an increased sensitivity to the chemotherapy treatment 39 and remarkable anti-proliferative and pro-apoptotic effects.

40 KEYWORDS

41 Barium titanate nanoparticles; piezoelectricity; wireless stimulation; glioblastoma multiforme;
42 blood-brain barrier.

43 INTRODUCTION

44 Despite the dramatic efforts to develop diagnostic and therapeutic tools, the treatment of 45 brain cancer remains a huge challenge in oncology, and successful treatments are still far from 46 being attained. The main obstacles to the successful treatment of brain tumors include *i*) the 47 structural complexity of the central nervous system, *ii*) the recurrence of the tumors, and *iii*) the 48 acquired drug resistance during chemotherapy.¹ The most common and detrimental primary brain 49 tumor among adults is represented by glioblastoma multiforme (GBM), a particularly aggressive 50 malignant astrocytoma. Although various treatments are available for GBM, including surgical resection, chemotherapy, and radiation, prognosis remains extremely poor.² The average survival 51 52 time following diagnosis of GBM patients is only fourteen months, while the five-year survival 53 rate is about 5%.

54 As alternative anticancer approaches, effective physical treatments based on low-intensity 55 alternating currents (AC) demonstrated great potential for inhibiting the proliferation of different kind of cancer cells without the use of any drug/chemical.^{3,4} Specifically, AC is known to inhibit 56 cell division by interfering with Ca²⁺ and K⁺ homeostasis and with the cytoskeletal components 57 58 involved in cell division. Low-intensity AC resulted able to enhance the efficacy of a standard 59 chemotherapy drug, temozolomide (TMZ), by reducing multidrug resistance,⁵ and have been 60 recently tested in combination with TMZ for the treatment of glioblastoma multiforme in clinical trials.^{6,7} The involved mechanism seems to be mediated by a AC-dependent translocation of the 61 drug transporter P-glycoprotein (P-gp) from the plasma membrane to the cytosol.⁵ However, 62 63 healthy brain cells (*i.e.*, human astrocytes) are also sensitive to AC-dependent antiproliferative 64 effects³ and, in this context, the local delivery of electrical stimuli to cancer cells is highly 65 desirable.

66 The rapid development of innovative nanotechnological tools is allowing for the targeting 67 of remote physical stimulations (*e.g.*, thermal, electrical, oxidative, ionic, *etc.*) in deep tissues.⁸ 68 In the field of nano-oncology, different nanotransducers have been designed to mediate 69 photothermal, photodynamic, or magnetothermal conversion, and to locally deliver anticancer stimuli at tumor level.⁹ These nanotechnology-assisted remote stimulation approaches exploit a 70 71 non-invasive source of energy, such as, for example, alternated magnetic fields and near-infrared 72 radiations, which penetrates the biological tissues and is finally transduced by the nanomaterial 73 into another potential toxic form of energy (e.g., heat). 74 In this context, our group proposed, for the first time in the literature, the remote electric stimulation of living cells mediated by piezoelectric nanoparticles,^{10,11} an extremely interesting 75 approach for the modulation of cell behavior and activities.^{12,13} Taking advantage of the direct 76 77 piezoelectric effect, these nanomaterials have been exploited to convert mechanical into electrical energy.^{14,15} Electric potentials can be generated by piezoelectric nanoparticles in 78 remote modality by using ultrasounds (US),¹⁶ mechanical pressure waves that can be safely and 79 efficiently conveyed into deep tissues. Electro-elastic mathematical models¹¹ allowed to estimate, 80 at nanoparticle level, the magnitude of the output voltage ($\varphi_{output} \sim 0.5 \text{ mV}$) evoked in response 81 to US intensity $I_{US} = 0.8 \text{ W/cm}^2$, while electrophysiological recordings¹⁷ and real-time Ca²⁺/Na⁺ 82 imaging¹¹ of electrically excitable cells experimentally demonstrated the efficacy of 83 84 nanoparticle-assisted piezo-stimulation. Recently, our group successfully exploited the 85 antiproliferative effects of nanoparticle-assisted remote electric stimulation as non-invasive "wireless" therapy suitable for inhibiting proliferation of SK-BR3 breast cancer cells.¹⁸ Similarly 86 87 to low-intensity AC, chronic piezo-stimulations resulted able to inhibit cancer cell cycle progression by interfering with Ca^{2+} homeostasis, by upregulating the gene expression of inward 88

rectifier potassium channels, and by affecting the developing of the mitotic spindles during cell
division.¹⁸

91 Associated to the difficulties of treatment of pathologies at the level of the central nervous 92 system, we find the problem of blood-brain barrier (BBB) crossing. The recent growth of 93 nanotechnology promises to revolutionize the delivery of nanomaterials across BBB to brain cancers.¹⁹ At first instance, the delivery of different nanomaterials through the BBB at the tumor 94 95 site can be efficiently obtained by taking advantage of the enhanced permeability and retention (EPR) effect.²⁰ This phenomenon is associated to a highly fenestrated and permeabilized BBB in 96 97 correspondence of newly formed tumor vessels. A complementary strategy, that appears to be 98 particularly relevant for diagnostic and therapeutic purposes, is the functionalization of 99 nanomaterials with specific ligands to promote their BBB crossing and their targeting to specific cell types or anatomical districts.²¹ Typical receptors on cancer cell membrane, as the folate, the 100 101 transferrin, or the epidermal growth factor (EGF) receptors, can be targeted for an efficient 102 delivery of nanostructures to cancer cells. Particular attention has been dedicated to the antibody 103 against the transferrin receptor (anti-TfR Ab), since it can be successfully exploited as a dualtargeting ligand for both enabling the BBB-crossing and the uptake by cancer cells.²²⁻²⁵ 104 105 In this work, we report the preparation of functionalized piezoelectric nanoparticles for *in vitro* 106 BBB crossing, active glioblastoma cell targeting, imaging, and remote electric treatment. To this 107 aim, tetragonal crystalline barium titanate nanoparticles (BTNPs) have been chosen as lead-free piezoelectric nanotransducers²⁶ because of their excellent level of biocompatibility,²⁷ high 108 piezoelectric coefficient ($d_{33} \sim 30 \text{ pm/V}$),²⁸ peculiar optical properties,²⁹⁻³¹ and possibility to 109 finely control their morphology.³² Finally, the synergic effects of the chronic piezoelectric 110 111 stimulation combined with sub-toxic TMZ treatment have been *in vitro* investigated.

112 MATERIALS AND METHODS

113 Nanoparticle functionalization with anti-TfR antibody (AbBTNPs)

114 Non-centrosymmetric piezoelectric barium titanate nanoparticles were purchased by 115 Nanostructured & Amorphous Materials, Inc (nominal nanoparticle size 300 nm in diameter, as 116 indicated by the provider, purity > 99.9%). In the literature, many different dispersing agents 117 have been adopted to obtain a stable dispersion of these nanoparticles, like poly(vinylpyrrolidone) (PVP),³³ hexamethylenetetramine (HMT),³⁴ ascorbic acid,³⁵ and 118 ethanolamine.³⁵ In this work, a wrapping with the amphiphilic 1,2-distearoyl-sn-glycero-3-119 120 phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] (DSPE-PEG, Nanocs, purity >121 99%) was carried out, as this copolymer allows for easy and straightforward functionalization with many kinds of targeting moieties¹⁸. DSPE-PEG was mixed with BTNPs (1:1 w/w) in 122 123 ddH₂O; the mixture underwent sonication with a tip sonicator (8 W for 150 s, Mini 20 Mandelin 124 Sonoplus) and, after a centrifugation step (20 min at 900 rcf, Hettich®Universal 320/320R 125 centrifuge), supernatant containing free DSPE-PEG was discharged. The wrapped nanoparticles 126 were thereafter washed twice in ddH_2O and finally re-dispersed at a 5 mg/ml concentration in 127 ddH₂O (for electron microscopy imaging), in PBS (for estimation of functionalization 128 efficiency), or in complete cell medium (for stability studies and for biological experiments). 129 Concerning the nanoparticle functionalization with the antibody against the transferrin 130 receptor, BTNPs were firstly coated with biotin-DSPE-PEG (20 % w/w, Nanocs, purity > 95%) 131 and DSPE-PEG (80 % w/w), and subsequently conjugated to streptavidin-Ab anti-TfR (2.5 µg of Ab / mg of BTNPs, Abcore), similarly as described in a previous work.¹⁸ Ab-functionalized 132 133 BTNPs will be indicated in the text as AbBTNPs. DPSE-PEG-coated BTNPs have been used as 134 control and will be indicated in the following as BTNPs for easiness of reading. The non-

135	functionalized plain BTNP powder will be indicated as plain BTNPs. The quantification of Ab
136	functionalization efficiency was carried out through the bicinchoninic acid (BCA) assay
137	following the manufacturers' procedures (enhanced test tube protocol, Thermo Fisher).
138	Nanoparticle size, Z-potential, and polydispersity of AbBTNP and BTNP suspension (100 μ g/ml)
139	were characterized by using dynamic light scattering (DLS, Nano Z-Sizer 90, Malvern
140	Instrument); the dynamic measurements of size and polydispersity were performed every ten
141	minutes for two hours. Fourier-transformed infrared spectroscopy (FT-IR) was performed using a
142	Shimadzu Miracle 10 as previously described. ³⁶
143	Multimodal imaging of BTNPs
144	Imaging of BTNPs was performed by using scanning electron microscopy (SEM), second
145	harmonic generation (SHG) microscopy, and confocal laser scanning microscopy (CLSM). A
146	drop of the diluted BTNP dispersion (100 μ g/ml) was deposited and let dry on a glass coverslip.
147	SHG imaging of tetragonal crystal lattice of piezoelectric BTNPs was carried out with a
148	multimodal custom-made non-linear microscope using a femtosecond pulsed laser source
149	(Discovery, Coherent Inc.) for excitation. Images were acquired using an excitation wavelength
150	of 800 nm and a 20X water immersion objective lens (XLUM 20X 0.95 NA, Olympus
151	Corporation). SHG signal at 400 nm was collected in the epi-direction using a dichroic filter.
152	Emission spectrum was obtained exciting with a pump-and-probe beam at 810 nm and a Stokes
153	beam at 1060 nm.
154	BTNPs were also detected by CLSM (C2s system, Nikon) with a 642 nm laser (emission
155	collected at 670 nm $< \lambda_{em} < 750$ nm), as showed elsewhere. ^{11,18,31} BTNP signal from SHG and
156	CLSM images related to the same region of the glass coverslip were obtained and then merged
157	with ImageJ software (https://imagej.nih.gov/ij/).

158 For SEM, the coverslip with the deposited nanoparticles was gold-sputtered at 60 nA for 25 s,

and imaging was carried out by using a Helios NanoLab 600i FIB/SEM, FEI.

160 Characterization of the blood-brain barrier model

161 Cultures of immortalized brain-derived endothelioma bEnd.3 cell line (ATCC® CRL-2299TM) were seeded at high confluence (seeding density $8 \cdot 10^4$ cells/cm²) and maintained in proliferative 162 163 conditions on 3 µm porous transwells (Corning Incorporated) in order to obtain a functional endothelial barrier mimicking the BBB.³⁷ In this configuration, endothelial layer separates the 164 165 luminal compartment (on the top) from the abluminal compartment (on the bottom). Both the 166 abluminal and luminal compartments were incubated with complete cell medium, composed by 167 Dulbecco's Modified Eagle's Medium (DMEM, Thermo Fisher Scientific), 10% fetal bovine 168 serum (FBS, Gibco), 100 IU/ml penicillin (Gibco), 100 µg/ml streptomycin (Gibco). 169 The development of a functional biological barrier was assessed at day 1, 3 and 6 of 170 proliferation by measuring both FITC-dextran permeability and transendothelial electric 171 resistance (TEER). BBB model permeability was analyzed by incubating the luminal 172 compartment with 200 µg/ml of FITC-dextran (Sigma, molecular weight 70 KDa) and measuring 173 the fluorescence emission ($\lambda_{ex} = 485 \text{ nm}$, $\lambda_{em} = 535 \text{ nm}$, Perkin Elmer Victor X3 UV-Vis 174 spectrophotometer) of the abluminal compartment at different time points (10, 20, 30, 60, 120 175 min). TEER was assessed with a Millipore Millicell ERS-2 Volt-Ohmmeter device. Resistance 176 across the plain transwell (blank) was subtracted to all the TEER measurements. After the 177 quantitative BBB model characterizations, all the subsequent experiments reported in the text 178 were performed on BBB models at day 3. The qualitative morphological integrity of the BBB 179 models at day 3 and the expression of a specific marker of tight junctions (*zonula occludens-1*) 180 were respectively verified by Coomassie[®] Brilliant Blue Staining (BioRad, 0.2% for 5 minutes)

and by immunocytochemistry (please refer to the Materials and methods "Immunofluorescencestaining").

183 Investigations of nanoparticle-cell interactions and BBB model crossing

BTNPs associated to bEnd.3 cells were observed with SEM imaging combined with energydispersive X-ray spectroscopy (EDX). Samples incubated for 30 min with 100 µg/ml BTNPs were washed twice in PBS and fixed with paraformaldehyde (PFA, 4 % in PBS). Subsequently, cells were washed twice with ddH₂O and treated with glutaraldehyde solution (2.5 % in ddH₂O for 30 min at 4°C) and dehydrated by using progressive ethanol gradients (0 %, 25 %, 50 %, 75 %, and 100 % in ddH₂O). Before SEM/EDX imaging (Helios NanoLab 600i FIB/SEM), samples were gold-sputtered as described above.

191 Concerning TEM imaging, samples incubated for 30 min with BTNPs or AbBTNPs were

192 washed twice with PBS, fixed with a solution of 1.5 % glutaraldehyde in sodium cacodylate

193 buffer (0.1 M, pH 7.4) and the pellet treated for epoxy resin embedding. Briefly, cells were post-

194 fixed in 1% osmium tetroxide plus 1% K₃Fe(CN)₆ at room temperature; then cells were *en bloc*

stained with 3 % solution of uranyl acetate in 20 % ethanol; finally, they were dehydrated and

196 embedded in epoxy resin (Epon 812, Electron Microscopy Science). Polymerization has been

197 performed for 48 h at 60°C. Samples were then sectioned with a UC7 Leica ultramicrotome

198 equipped with a 45° diamond knife (DiATOME), and the slices of 80-90 nm were collected on

199 300 mesh copper grids. The ultrastructural analysis was performed by using a Zeiss Libra 120

200 Plus instrument operating at 120 kV equipped with an in-column omega filter.

201 Fluorescence staining of plasma membranes and acidic organelles in living bEnd.3 cells was

202 carried out. For these experiments, bEnd.3 cells were seeded on 35 mm μ -dish (Ibidi) at 8.10⁴

203 cells/cm² density for 3 days and then incubated with 100 μ g/ml BTNPs / AbBTNPs for 24 and 72

204	h. After nanoparticle treatment, cells were washed in PBS and stained with CellMask Green
205	Plasma Membrane Stain (1:1000 dilution; Invitrogen) or with Lysotracker (50 nM; Invitrogen)
206	following the manufacturers' procedures. Nuclear staining was performed with Hoechst 33342 (1
207	μ g/ml, Invitrogen) in all samples. Finally, cells were washed and incubated with HEPES-
208	supplemented (25 mM) phenol red-free DMEM (Thermo Fisher) supplemented with 10% of FBS
209	for CLSM imaging (C2s system, Nikon). Images were acquired by using the same acquisition
210	parameters for the different experimental classes and were subsequently analyzed with NIS-
211	Elements software (Nikon). Concerning the analysis of nanoparticle internalization, signals of
212	plasma membranes and nanoparticles were selected and then measured upon intensity
213	thresholding. Intersections between the areas of BTNPs / AbBTNPs and plasma membranes or of
214	nanoparticles and intracellular regions were then obtained and expressed as percentages of the
215	total nanoparticle area. Co-localization between acidic organelles and nanoparticles was
216	investigated by assessing Mander's overlap coefficient. 3D reconstruction of z-stack images was
217	carried out by using NIS-Elements software (Nikon).
218	Investigations of nanoparticle internalization were also performed on U-87 cells (ATCC ®
219	HTB-14), a cell line derived from a human primary glioblastoma that is well characterized and
220	commonly used in brain cancer research. ³⁸ The composition of the medium used for culturing U-
221	87 cells was the same of that for bEnd.3 cells (U-87 seeding density $2 \cdot 10^4$ cells/cm ²).
222	Internalization studies were performed by incubating 100 μ g/ml of nanoparticles directly on U-
223	87 cells seeded on 35 mm μ -dish (Ibidi). Alternatively, U-87 cells were seeded in the abluminal
224	compartment of the transwell and 100 μ g/ml of nanoparticles were dispersed in cell medium of
225	the luminal compartment. Staining, CLSM imaging, and image analysis were carried out as
226	described above for bEnd.3 cells. SHG imaging of nanoparticle internalization was carried out

227	with the multimodal custom-made non-linear microscope described above, exploiting a pump-
228	and-probe beam at 800 nm and a Stokes beam at 1040 nm. Coherent anti-Stokes Raman
229	spectroscopy (CARS) signal at 650 nm and SHG signal from pump beam at 400 nm were
230	acquired simultaneously in epi-direction.
231	BBB model-crossing was investigated through flow cytometry (CytoFLEX, Beckman
232	Coulter). 100 μ g/ml of nanoparticles were incubated in the luminal compartments of a BBB
233	model. At 4 h, 24 h and 72 h of nanoparticle treatment, concentrations of BTNPs / AbBTNPs
234	were assessed in the abluminal compartments. The number of events measured by flow
235	cytometry was then converted to nanoparticle concentrations thanks to a calibration curve
236	obtained at different known concentrations of BTNPs ($R^2 = 0.997$, Figure S1).
237	Chronic ultrasound (US) stimulations and temozolomide (TMZ) treatment
238	US were generated by a KTAC-4000 device (Sonidel) through a tip transducer (S-PW 3 mm
239	diameter tip). Chronic US stimulations were applied with 1 W/cm ² intensity and 1 MHz
240	frequency. Single US stimuli lasted 200 ms and were delivered every 2 s, 1 h per day, for 4 days.
241	This protocol of US treatment was chosen since was not able to detectably increase the
242	temperature of the cell medium neither to affect cell behavior / proliferation. ^{17,18}
243	Concerning TMZ treatment, different concentrations of the drug (0-400 μ g/ml) were assessed
244	at 24 and 72 h in order to evaluate TMZ effects. The highest non-toxic concentration (50 μ g/ml)
245	was then tested in combination with US stimulations.
246	Cell viability assays
247	Metabolism of cell cultures after the treatment with temozolomide (TMZ, Sigma-Aldrich) and
248	after chronic US stimulation was assessed with WST-1 Assay Reagent ((2-(4-iodophenyl)-3-(4-
249	nitrophenyl)-5- (2,4-disulfophenyl)-2H-tetrazolium sodium salt, BioVision), as previously

described.³⁹ Samples were washed twice with PBS and then incubated with the WST-1 reagent
(1:10 dilution in complete medium with phenol red-free DMEM, 50 minutes at 37°C). The
absorbance of the collected supernatants was measured with a multiplate reader (Perkin Elmer
Victor X3 UV-Vis spectrophotometer); the blank, corresponding to the non-specific absorbance
of the WST-1 dilution in phenol red-free DMEM, was subtracted from all measurements. Finally,
all data were normalized with respect to the non-treated controls.

256 Immunofluorescence staining

257 Immunofluorescence was carried out to detect the expression of the tight junction marker 258 zonula occludens-1 (ZO-1) in the BBB model. PFA-fixed cells were incubated with a 0.1% 259 Triton X-100 solution in PBS (25 min at room temperature) for membrane permeabilization and 260 with 10% goat serum in PBS (1 h at room temperature) as a blocking solution. Subsequently, 261 samples were treated with rabbit IgG primary antibody against ZO-1 (Invitrogen, 1:100 dilution 262 in PBS supplemented with 10% goat serum, 3 h at room temperature) and, after 5 washes with 263 PBS supplemented by 10% goat serum, were incubated with goat Alexa Fluor 488-IgG anti-264 rabbit secondary antibody (Invitrogen, 1:200 dilution in PBS supplemented with 10% goat 265 serum, 2 h at room temperature). TRITC-conjugated phalloidin (100 µM, Millipore) and Hoechst 266 33342 (1 µg/ml, Invitrogen) were also included in solution with the secondary antibody in order 267 to stain f-actin and nuclei, respectively.

268 Double immunofluorescence was performed to analyze the expression of the Ki-67

269 proliferation marker and of the p53 tumor suppressor marker on U-87 cells after 4 days of remote

270 chronic piezoelectric stimulation and TMZ treatment. Immunocytochemistry was performed as

described above with a primary mouse monoclonal anti-p53 antibody (Abcam, 1:200), a primary

272 rabbit IgG anti-Ki-67 antibody (Millipore, 1:150), a TRITC-conjugated secondary anti-rabbit

antibody (1:200, Millipore), and a FITC-conjugated secondary anti-mouse antibody (1:75,
Millipore).

275 Ca^{2+} imaging

276 Ca²⁺ imaging was performed during US stimulation, with or without piezoelectric AbBTNPs,

taking advantage of Fluo-4 AM Ca²⁺-sensitive fluorescence dye, similarly as in a previous

work.¹¹ Before US stimulation, U-87 cells were stained with Fluo-4 AM (Invitrogen, 1 µM in

279 DMEM for 30 min at 37°C), washed twice with PBS and incubated with HEPES-supplemented

280 (25 mM) phenol red-free DMEM (Thermo Fisher). Fluorescence time-lapse imaging was

281 performed with CLSM (C2s system, Nikon), and obtained images were processed by using

282 ImageJ (http://rsbweb.nih.gov/ij/). The average intracellular fluorescence intensity was defined

as F_0 at time t = 0 s, and as F for t > 0 s. F/F_0 values were calculated for both US and

AbBTNPs+US experimental groups and reported in the graph.

285 Statistics

For multiple sample comparisons, ANOVA followed by Tukey's HSD *post-hoc* test was

287 performed by using *R* software (https://www.r-project.org/); regarding the analysis of

288 nanoparticle internalization in bEnd.3 and U-87 cells, independent two-sample *t*-tests were

289 carried out by using Excel software. Statistically significant differences among distributions were

indicated for p < 0.05. Finally, data were plotted in histograms as average \pm standard error by

using Excel software.

292 RESULTS

293 The scheme of the experimental design is represented in Figure 1. In Figure 1a the strategy of

294 nanoparticle functionalization is depicted: piezoelectric BTNPs (showed in red) are wrapped

295 with DSPE-PEG and DSPE-PEG-biotin, and subsequently conjugated with strepatavidin-Ab

against human TfR to finally obtain AbBTNPs. In Figure 1b the luminal (in red) and abluminal

297 (in light blue) compartments of the *in vitro* BBB model are showed, where bEnd.3 and U-87

298 cells are respectively seeded (cell membranes are shown in green, nuclei in blue, and AbBTNPs

in red). After 72 h of nanoparticle incubation in the luminal compartment, U-87 cells exposed to

300 nanoparticles that crossed the BBB model have been piezoelectrically stimulated with chronic

301 US treatments, as schematically indicated in Figure 1c.

302 Characterization and imaging of piezoelectric BTNPs

Imaging of piezoelectric BTNPs is presented in Figure S2. Figure S2a reports a representative SEM image of the sample. Figure S2b represents the emission spectrum obtained by illuminating the tetragonal crystal lattice of piezoelectric BTNPs with a pair of spatially- and temporallyoverlapped laser beams at 810 nm and 1060 nm (pump-and-probe beam and Stokes beam, respectively). Figure S2c shows the multi-modal imaging of piezoelectric BTNPs; signal of BTNPs observed by SHG of the pump beam (in red) co-localizes with that one detected by CLSM (in green).

310 Fourier transformed infrared spectroscopy (FT-IR) was performed in order to verify the 311 successful functionalization of the BTNPs. Starting from the low wavelengths, the peaks in the range 530-600 cm⁻¹ (Figure S3) can be attributed to the Ti-O stretching bond and they are 312 characteristic of the BaTiO₃ compound.⁴⁰ Shifting to higher wavelengths, the peak at 1450 cm⁻¹ 313 314 that can be seen in spectrum i) of plain BTNPs can be attributed to an impurity of BaCO₃ as it has been reported elsewhere.⁴⁰ The peaks between 1000-1100 cm⁻¹ (spectrum ii)) are attributed to 315 the C-O-C and C-O-H stretching⁴¹ vibration of the aliphatic chain of poly(ethylene glycol) 316 (PEG), while the peaks in the range 1600-1670 and 1300-1460 cm⁻¹ (spectrum *iii*)) can be 317 attributed to the Amide I (C=O stretching)⁴² and Amide III⁴⁰ vibrations of the attached anti-318

319	transferrin antibody. The peaks at 2280-2400 and 2850-3000 cm ⁻¹ (spectra <i>ii</i>) and <i>iii</i>)) are
320	attributed to the C-H stretching bond of the DSPE-PEG while the peak at 3320 cm ⁻¹ (spectrum
321	iii)) can be attributed both to the O-H stretching vibration of the DSPE-PEG/TfR antibody as
322	well as to the Amide A (N-H stretching) ⁴³ of the TfR antibody. The corresponding vibrations and
323	wavelengths are summarized in Table S1. A small yet significant difference in Z-potential was
324	observed between BTNPs (-29.6 \pm 0.8 mV) and AbBTNPs (-22.0 \pm 0.6 mV), thus further
325	supporting the hypothesis of the successful functionalization of BTNPs with the Ab.
326	Quantitative measurements of functionalization efficiency indicated an amount of $1.1\pm0.4~\mu g$
327	of Ab per mg of BTNPs (~ 44% of the Ab used for the reaction successfully linked to BTNPs).
328	Considering the molecular weight of the Ab (~ 90 KDa) and the number of BTNPs per mg of
329	powder ($1.2 \cdot 10^{10}$ particles / mg), about 624 ± 227 molecules of Ab were conjugated to each
330	BTNP.
330331	BTNP. Polydyspersity index (PDI) and hydrodynamic diameter (<i>Rd</i>) of BTNPs and AbBTNPs were
331	Polydyspersity index (PDI) and hydrodynamic diameter (Rd) of BTNPs and AbBTNPs were
331 332	Polydyspersity index (PDI) and hydrodynamic diameter (<i>Rd</i>) of BTNPs and AbBTNPs were investigated (Figure S4). The PDI was found stable over time for both BTNPs and AbBTNPs
331332333	Polydyspersity index (PDI) and hydrodynamic diameter (<i>Rd</i>) of BTNPs and AbBTNPs were investigated (Figure S4). The PDI was found stable over time for both BTNPs and AbBTNPs (Figure S4a; 1 measurement / 10 min for 110 min total; for $t = 0$ min, 0.29 ± 0.05 for BTNPs and
331332333334	Polydyspersity index (PDI) and hydrodynamic diameter (<i>Rd</i>) of BTNPs and AbBTNPs were investigated (Figure S4). The PDI was found stable over time for both BTNPs and AbBTNPs (Figure S4a; 1 measurement / 10 min for 110 min total; for $t = 0$ min, 0.29 ± 0.05 for BTNPs and 0.25 ± 0.02 for AbBTNPs; for $t = 110$ min, 0.37 ± 0.04 for BTNPs and 0.37 ± 0.04 for
 331 332 333 334 335 	Polydyspersity index (PDI) and hydrodynamic diameter (<i>Rd</i>) of BTNPs and AbBTNPs were investigated (Figure S4). The PDI was found stable over time for both BTNPs and AbBTNPs (Figure S4a; 1 measurement / 10 min for 110 min total; for $t = 0$ min, 0.29 ± 0.05 for BTNPs and 0.25 ± 0.02 for AbBTNPs; for $t = 110$ min, 0.37 ± 0.04 for BTNPs and 0.37 ± 0.04 for AbBTNPs); in both cases $0.2 < PDI < 0.4$, thus indicating a moderate dispersivity. ⁴⁴
 331 332 333 334 335 336 	Polydyspersity index (PDI) and hydrodynamic diameter (<i>Rd</i>) of BTNPs and AbBTNPs were investigated (Figure S4). The PDI was found stable over time for both BTNPs and AbBTNPs (Figure S4a; 1 measurement / 10 min for 110 min total; for $t = 0$ min, 0.29 ± 0.05 for BTNPs and 0.25 ± 0.02 for AbBTNPs; for $t = 110$ min, 0.37 ± 0.04 for BTNPs and 0.37 ± 0.04 for AbBTNPs); in both cases $0.2 < PDI < 0.4$, thus indicating a moderate dispersivity. ⁴⁴ Furthermore, hydrodynamic diameter <i>Rd</i> of both samples were stable along the experiment
 331 332 333 334 335 336 337 	Polydyspersity index (PDI) and hydrodynamic diameter (<i>Rd</i>) of BTNPs and AbBTNPs were investigated (Figure S4). The PDI was found stable over time for both BTNPs and AbBTNPs (Figure S4a; 1 measurement / 10 min for 110 min total; for $t = 0$ min, 0.29 ± 0.05 for BTNPs and 0.25 ± 0.02 for AbBTNPs; for $t = 110$ min, 0.37 ± 0.04 for BTNPs and 0.37 ± 0.04 for AbBTNPs); in both cases $0.2 < PDI < 0.4$, thus indicating a moderate dispersivity. ⁴⁴ Furthermore, hydrodynamic diameter <i>Rd</i> of both samples were stable along the experiment (Figure S4b; 1 measurement / 10 min for 110 min total; for $t = 0$ min, $Rd = 274 \pm 1$ nm for

341 In order to obtain a functional biological barrier mimicking the BBB, confluent cultures of 342 bEnd.3 cells were maintained in proliferative conditions on 3 µm porous transwell for 1, 3 and 6 343 days (BBB model characterization is reported in Figure S5). Transendothelial electric resistance 344 (TEER) was measured to assess the performances of the barrier at the different time points 345 (Figure S5a). After 3 and 6 days of maturation, BBB model showed similar TEER levels (41.9 \pm 8.9 $\Omega \cdot \text{cm}^2$ and 48.5 \pm 7.4 $\Omega \cdot \text{cm}^2$ at day 3 and day 6 of culture, respectively), in both cases 346 significantly higher with respect to the 1 day culture ($20.1 \pm 0.9 \ \Omega \cdot cm^2$; p < 0.05). The crossing 347 348 of FITC-dextran through the BBB model (at day 1, 3 and 6 of maturation) is shown in Figure 349 S5b and has been expressed as % of the maximum theoretically achievable fluorescence intensity 350 in the abluminal compartment at different time points (10, 20, 30, 60 and 120 min). BBB model 351 at day 3 and day 6 showed similar permeability to FITC-dextran after 20 min of incubation (19.8 352 $\pm 0.6\%$ at day 3 and 17.8 $\pm 0.4\%$ at day 6), while a significant lower permeability at day 6 of 353 maturation $(35.1 \pm 1.7\%)$ was observed after 120 min of dextran treatment with respect to both 354 day 1 and day 3 (101.2 \pm 2.7% at day 1 and 52.3 \pm 2.4% at day 3; p < 0.05). The developing of 355 cell multilayers was also observed at day 6. Considering the good performances of the BBB 356 model at day 3 as well as the scarce mechanical stability and resistance to the shear forces of 357 BBB immediately after day 6 (delamination and cell layer detachments were observed in 358 different cultures starting from day 7-8), nanoparticle-crossing through barrier was tested on 359 BBB starting from day 3. In Figure S5c the Coomassie (left image) and the immunofluorescence 360 staining (right image, ZO-1 in green and nuclei in blue) of the 3-day BBB model are reported; it 361 is possible to appreciate the complete maturation of functional junctions among bEnd.3 cells, 362 that develop a endothelial layer separating the luminal from abluminal compartment of the 363 transwell.

364	Analysis of BTNP / AbBTNPs interacting with bEnd.3 cells and assessment of BBB model
365	crossing are shown in Figure 2. In Figure 2a the SEM imaging and the energy dispersive X-ray
366	analysis (EDX) of BTNPs associated to the plasma membranes of bEnd.3 cells are reported.
367	Qualitatively, TEM observations (Figure 2b) highlighted a higher amount of AbBTNPs
368	associated to plasma membranes and up-taken by bEnd.3 cells with respect to the non-
369	functionalized BTNPs. CLSM of immunofluorescence staining against the ZO-1 marker of tight
370	junctions after 72 h of BTNP / AbBTNP treatment is showed in Figure 2c (nuclei in blue, f-actin
371	in red, ZO-1 in green, nanoparticles in white). CLSM imaging revealed that both BTNPs and
372	AbBTNPs were internalized in bEnd.3 cells; however, increased nanoparticle internalization can
373	be appreciated in samples treated with AbBTNPs. Plasma membrane imaging was carried out at
374	72 h of nanoparticle treatment (Figure 2d) and showed a higher amount of nanoparticles
375	internalized in cell body with respect to those associated to the plasma membranes (this was
376	observed for both BTNPs and AbBTNPs). Histograms of Figure 2e and 2f show the cell
377	membrane and intracellular areas (%) of bEnd.3 cells co-localizing with BTNPs / AbBTNPs at
378	24 and 72 h of nanoparticle incubation, respectively. The quantitative analysis demonstrates a
379	significantly higher amount of AbBTNPs, both associated to membranes (1.06 \pm 0.27%) and
380	internalized by bEnd.3 cells (2.04 \pm 0.30%), with respect to BTNPs (0.30 \pm 0.14% associated to
381	plasma membranes and 0.55 \pm 0.31% internalized in cells; $p < 0.05$) at 24 h. Furthermore, the
382	amount of intracellular nanoparticles (both AbBTNPs and BTNPs) decreased from 24 to 72 h
383	(AbBTNPs and BTNPs internalized in cells for 72 h correspond, respectively, to $1.02 \pm 0.14\%$
384	and 0.24 \pm 0.05%), likely due to the active transport mechanisms through the bEnd.3 cells (<i>e.g.</i> ,
385	transcytosis and exocytosis). Despite this decrement, the amount of functionalized nanoparticles
386	internalized in bEnd.3 cells remained significantly higher with respect to BTNPs at 72 h ($p <$

387	0.05). 3D reconstructions of nanoparticles (BTNPs / AbBTNPs in red) and bEnd.3 plasma
388	membranes (in green) are available in Figure S6 (72 h of incubation). Moreover, co-localization
389	analysis of nanoparticles and acidic cell compartments (i.e., late endosomes and lysosomes) at 4,
390	24 and 72 h of BTNP / AbBTNP incubation is reported in Figure S7, and showed a progressive
391	accumulation in the acidic organelles of the cells. Higher AbBTNPs co-localization with acidic
392	cell compartment was found with respect to BTNPs at both 24 h (Mander's coefficients were
393	0.56 ± 0.06 for AbBTNPs and 0.36 ± 0.03 for BTNPs; $p < 0.05$) and 72 h (Mander's coefficients
394	were 0.78 \pm 0.14 for AbBTNPs and 0.36 \pm 0.07 for BTNPs; <i>p</i> < 0.05), presumably as a
395	consequence of the higher internalization level with respect to the non-functionalized ones.
396	In order to measure BBB model-crossing, BTNP / AbBTNP were incubated in the luminal
397	compartment of the BBB model and nanoparticle concentrations in the abluminal compartment
398	were measured at 4, 24 and 72 h of nanoparticle treatment. Results reported a progressive BBB-
399	crossing of BTNPs / AbBTNPs at the different time points. Similar BTNP and AbBTNP
400	concentrations were found at 4 h (3.25 \pm 0.01 $\mu g/ml$ and 2.96 \pm 0.26 $\mu g/ml$ respectively for
401	BTNP and AbBTNP) and 24 h (6.26 \pm 0.83 $\mu g/ml$ and 6.72 \pm 0.10 $\mu g/ml$ respectively for BTNP
402	and AbBTNP). Instead, a significantly higher BBB-crossing ability of AbBTNPs was observed at
403	72 h with respect to non-functionalized nanoparticles (~34% increase: 8.01 \pm 0.03 $\mu g/ml$ and
404	$10.69 \pm 0.17 \ \mu$ g/ml respectively for BTNP and AbBTNP; $p < 0.05$). All together, these results
405	indicated a higher BBB-targeting and BBB-crossing efficiency of the functionalized nanosystem.
406	Dual targeting of AbBTNPs
407	Additionally to the measurements of nanoparticle concentration in the abluminal compartment,
408	the ability of AbBTNPs to efficiently bind glioblastoma cells was tested (Figure 3). CLSM

409 analysis of U-87 cells that were incubated for 24 h with 100 μ g/ml BTNPs or AbBTNPs is

410	shown in Figures 3a-b. Interestingly, a higher level of AbBTNPs ($1.00 \pm 0.23\%$ intracellular
411	nanoparticles and $1.32 \pm 0.42\%$ associated to membranes) were found with respect to BTNPs
412	$(0.16 \pm 0.03\%$ intracellular nanoparticles and $0.26 \pm 0.11\%$ associated to membranes; $p < 0.05$).
413	Qualitative observations with CARS / SHG scans confirmed the higher level of AbBTNP
414	internalization (Figure 3c). Moreover, the CLSM analysis of U-87 cells exposed to nanoparticles
415	that crossed the BBB model was carried out; Figure 3d shows representative CLSM images of
416	U-87 cells cultured in the abluminal compartment after a 72 h treatment with BTNPs or
417	AbBTNPs in the luminal compartment. In Figure 3e, the quantitative co-localization analysis
418	revealed a higher amount of AbBTNPs in the abluminal compartment that are associated to the
419	plasma membranes (1.11 \pm 0.35%) and internalized by U-87 cells (0.96 \pm 0.25%) compared to
420	BTNPs (0.38 \pm 0.15% associated to plasma membranes and 0.16 \pm 0.03%; internalized by U-87
421	cells; $p < 0.05$), thus demonstrating as the AbBTNPs resulted a successful nanosystem able to
422	cross the in vitro BBB model and to target U-87 cells with higher efficiency with respect to the
423	non-functionalized BTNPs. For this reason, the following experiments have been performed just
424	by using AbBTNPs.
425	Chronic piezoelectric stimulation inhibits proliferation of human glioblastoma cells
426	Inhibitory effects of chronic piezoelectric stimulation on U-87 proliferation are shown in
427	Figure 4. Two concentrations of AbBTNPs have been investigated: 100 μ g/ml, already
428	successfully tested on SK-BR3 breast cancer cells, ¹⁸ and 10 μ g/ml, the concentration of
429	nanoparticles able to cross the BBB model after 72 h. The expression of the nuclear proliferation
430	marker Ki-67 has been analyzed through immunofluorescence assays combined with CLSM
431	imaging (Figure 4a). Qualitatively, it is possible to appreciate a lower Ki-67 expression in
432	piezoelectrically-stimulated cells ($\Delta hBTNPs \pm US$) with respect to the control cultures (non-

432 piezoelectrically-stimulated cells (AbBTNPs+US) with respect to the control cultures (non-

433 stimulated and non-incubated controls, cells incubated with AbBTNPs but non-stimulated with 434 US, cultures stimulated with US without the presence of AbBTNPs); quantitative analysis of Ki-435 67⁺ nuclei (%) are presented in Figure 4b and reported as the lowest proliferation rate was found 436 for AbBTNPs+US cultures incubated with 100 μ g/ml of nanoparticles (28.7 \pm 2.5%), followed 437 by AbBTNPs+US cultures incubated with 10 μ g/ml of nanoparticles (51.1 ± 4.5%). Both these 2 438 experimental conditions resulted characterized by a significantly lower proliferation rate with 439 respect to all the other control groups (72.3 \pm 3.7% for non-stimulated and non-incubated 440 controls, $77.4 \pm 3.2\%$ for cells incubated with AbBTNPs but non-stimulated with US, $86.8 \pm$ 441 1.9% for cultures stimulated with US without the presence of AbBTNPs; p < 0.05). Time-lapse Ca^{2+} imaging on AbBTNPs+US (10 µg/ml) cultures demonstrated the successful 442 remote activation of the cells (Figure 4c): remarkable long-term Ca^{2+} waves are observed in 443 response to the US stimulation in the presence of the nanoparticles. The peak of the Ca^{2+} wave 444 was detected ~ 5 min after starting the US stimulations, and the Ca^{2+} concentrations remain 445 higher than the basal levels even after 25 min of stimulation. The time lapses video of Ca^{2+} 446 447 imaging performed on US and AbBTNPs+US cultures are available as Supplementary Information (Video S1 and S2, respectively). The stability of Ca^{2+} levels and the regular 448 449 proliferation rate observed in response to the plain US stimulation (*i.e.*, without the presence of 450 AbBTNPs) support the safeness of the proposed stimulation method. 451 Synergic efficacy of remote piezoelectric stimulation with temozolomide treatment 452 The ability of nanoparticle-assisted piezoelectric stimulation to improve the anticancer efficacy 453 of temozolomide (TMZ) treatment was investigated (Figure 5). Toxic effects of TMZ were 454 assessed by testing different concentrations of the chemotherapy treatment (0-400 µg/ml) at two 455 different time points (24 and 72 h) through WST-1 assay (data are normalized and expressed as

456 percentage of WST-1 absorbance values measured at 24 h on control cultures). Metabolism of U-457 87 cultures at 72 h of treatment was significantly affected when treating with concentrations at 458 least of 200 μ g/ml (Figure 5a): the best anti-proliferative effects were observed with the highest 459 tested TMZ concentration (400 μ g/ml), while first significant effects were observed by using 200 460 µg/ml. The hypothesis that piezoelectric stimulation could increase the sensitivity of TMZ was 461 investigated by using 50 μ g/ml of this chemotherapy drug, the highest concentration that was not 462 effective in our testing conditions (Figure 5b-e). Experimental classes we represented by control 463 cultures, cultures incubated with 10 μ g/ml AbBTNPs, cultures incubated with 50 μ g/ml TMZ, 464 cultures incubated with 50 µg/ml TMZ and 10 µg/ml AbBTNPs, cultures chronically stimulated 465 with US, cultures stimulated with US in the presence of 10 µg/ml AbBTNPs, cultures stimulated 466 with US in the presence of 50 µg/ml TMZ, and, finally, cultures stimulated with US in the 467 presence of 10 µg/ml AbBTNPs and of 50 µg/ml TMZ. WST-1 assay (Figure 5b) was performed 468 at day 4 on control cultures (100.0 \pm 7.2%), cultures incubated with AbBTNPs (101.3 \pm 1.7%), 469 cultures incubated with TMZ (97.4 \pm 2.4%), cultures incubated with TMZ and 10 μ g/ml 470 AbBTNPs (95.3 \pm 0.9%), cultures chronically stimulated with US (94.9 \pm 4.5%), cultures 471 stimulated with 10 μ g/ml AbBTNPs+US (87.8 \pm 1.3%), cultures stimulated with US and TMZ 472 $(94.7 \pm 4.1\%)$, and, finally, cultures stimulated with 10 µg/ml AbBTNPs+US in the presence of 473 TMZ (TMZ+AbBTNPs+US; $72.1 \pm 1.7\%$). Results confirmed the anti-proliferative effects of 474 nanoparticle-assisted piezoelectric stimulation (AbBTNPs+US), that was able to significantly 475 decrease the metabolic activity without the presence of TMZ with respect to the other control 476 conditions (control, AbBTNPs, TMZ, AbBTNPs+TMZ, US, US+TMZ; p < 0.05). However, the 477 major effects were observed by synergistically combining piezo-stimulation with TMZ 478 (TMZ+AbBTNP+US; p < 0.05).

479 The expression of the Ki-67 proliferation marker and of the p53 tumor suppressor marker in 480 response to 50 µg/ml TMZ, 10 µg/ml AbBTNPs+US, and of 10 µg/ml AbBTNPs+US with 50 481 µg/ml TMZ (TMZ+AbBTNPs+US) were compared with control cultures and are showed in 482 Figure 5c. Qualitatively, a decreased number of cells and a lower Ki-67 expression were found in 483 both AbBTNP+US and TMZ+AbBTNP+US experimental classes, compared to both control and 484 TMZ. This observation is in line with the lowest metabolism levels reported in response to these 485 treatments. Moreover, a higher amount of $p53^+$ nuclei was detected in response to 486 TMZ+AbBTNP+US treatment with respect to the other experimental groups. Quantitatively, Ki-487 67^+ nuclei in control (72.4 ± 2.8%) and in TMZ-treated (65.8 ± 5.7%) cultures were significantly 488 higher with respect to the cultures treated with AbBTNP+US (49.2 \pm 3.7%; p < 0.05) and with 489 TMZ+AbBTNP+US (27.7 \pm 2.5%; p < 0.05), the last of which resulted the strongest 490 antiproliferative treatment (p < 0.05; Figure 5d). Higher levels of p53⁺ nuclei were found in 491 response to the combined TMZ+AbBTNP+US therapy (28.3 \pm 6.6%; p < 0.05; Figure 5e) with 492 respect to all the other treatments $(1.2 \pm 1.3\%)$ for AbBTNP+US; $3.4 \pm 1.1\%$ for TMZ) and 493 control cultures $(1.0 \pm 0.7\%)$. 494 Overall, these results indicate that piezoelectric stimulation affects proliferation of U-87 cells

494 Overall, these results indicate that prezoelectric stimulation affects promeration of 0-87 cens
 495 and increases their sensitivity to TMZ. Indeed, TMZ therapy at non-toxic concentrations, when
 496 combined with chronic piezoelectric treatment, was able to promote cell apoptosis and reducing
 497 cell proliferation.

498 DISCUSSION

499 Recent advances in nanobiotechnology are directed to the development of smart and

500 biocompatible sensors / actuators that are able to detect and respond to specific physicochemical

501 conditions in the human body.⁴⁵⁻⁴⁷ Piezoelectric nanomaterials are a promising class of

502 nanostructures, that have been successfully exploited both as mechanical sensors for energy-

harvesting and mechanobiology studies, and as nanostimulators for indirect electrical activation
 of excitable cells.^{48,49}

505 In this work, we report for the first time the successful crossing of a piezoelectric nanomaterial 506 through a BBB model. Piezoelectric barium titanate nanoparticles used in this study are 507 characterized by a 300 nm diameter size, and resulted able to cross a BBB model with a quite 508 good efficiency; crossing was however improved of ~30% by promoting nanoparticle targeting 509 to BBB cells thanks to surface functionalization with anti-TfR Ab. These results are in line with 510 observations of Wohlfart *et al.*, that reviewed various nanoparticles adopted for the delivery of 511 different drugs into the brain and reported as most of the successfully ones are characterized by a size ranging from 150 to 300 nm.⁵⁰ Moreover, nanoparticles of 300 nm size are still small 512 513 enough to passively cross the large defenestrations of the tumor-associated vessels developed during aberrant angiogenesis.^{11,51} Indeed, the cutoff size of porous blood vessels in most of 514 515 tumors is 380-780 nm, and 400 nm size nanoparticles are known to efficiently accumulate in the brain tumors.⁵² These considerations are extremely important in view of exploiting piezoelectric 516 517 BTNPs for *in vivo* and preclinical studies, especially considering the potential impact of these 518 nanomaterials in nanomedicine, not only for brain cancer treatment, yet also for the non-invasive 519 electric deep brain treatment of different neurodegenerative pathologies that are characterized by a defenestrated vasculature, such as Parkinson's and Alzheimer's diseases.⁵³ 520 521 The higher levels of AbBTNPs associated to plasma membranes and internalized in cell body 522 with respect to BTNPs confirm the efficacy of the dual targeting strategy mediated by the

523 antibody against TfR, a receptor highly expressed by the endothelial cells of the

524 neurovascolature⁵⁴ and by different cancer cells (*i.e.*, glioma, lymphoma, leukemia, breast, lung,

bladder).^{55,56} In agreement with our observations, Cui et al. and Chang et al. exploited TfR 525 526 targeting to promote the targeting of poly(lactic-co-glycolic acid) (PLGA) nanoparticles to 527 glioblastoma cells, both in vitro and in vivo. In these cited works, PLGA nanoparticles were 528 functionalized with Tf. However, recent researches reported a decrease of specificity of Tf-529 functionalized nanosystems in biological environment due to the high levels of endogenous free Tf.⁵⁷ Therefore, following an approach adopted also by other groups,^{58,59} we performed 530 531 nanoparticle functionalization with anti-TfR Ab, that does not compete with endogenous Tf for 532 TfR binding. The cell-targeting efficiency of our nanoplatform was investigated by exploiting 533 different imaging techniques, as SEM/EDX, TEM, CLSM and SHG, the last of which represents 534 an advanced imaging technique allowing detecting the crystal asymmetry of BTNP tetragonal 535 lattice. Taking advantage of these imaging approaches, nanomaterial was detected in biological 536 samples without the need of any kind of surface modification (e.g., with fluorophore 537 functionalization or quantum-dot decoration) that can potentially interfere with nanomaterial-cell 538 interaction and with its internalization fate. In this regard, thanks to their peculiar optical properties, non-centrosymmetric BTNPs display a potential impact for cancer theranostics.³¹ 539 540 Concerning piezoelectric stimulation, AbBTNP+US treatment resulted able to affect the 541 proliferation of different types of cancer cells, thus suggesting a high versatility of this anticancer 542 approach. Particularly, we observed a remarkable decrease of proliferative U-87 cells after 4 days of chronic piezo-stimulation (from $86.8 \pm 1.9\%$ of Ki- 67^+ nuclei, observed in control cultures, to 543 $28.7 \pm 2.5\%$ of Ki-67⁺ nuclei, when stimulating with 100 µg/ml AbBTNPs+US); the decrease in 544 545 U-87 cell proliferation in response to piezoelectric stimulation was even more pronounced with respect to that observed on SK-BR-3 cells (from $80 \pm 8\%$ of Ki-67⁺ nuclei observed in control 546 547 cultures to $56 \pm 13\%$ of Ki-67⁺ nuclei when stimulating with 100 µg/ml AbBTNPs+US).

548 Moreover, the anti-proliferative effects of piezoelectric stimulation resulted preserved, albeit to a 549 lesser extent, when reducing nanoparticle concentration to 10 µg/ml (corresponding to the 550 concentration of nanoparticles that crossed the BBB model after 72 h). No significant increases 551 of apoptotic glioblastoma cells were observed when treating cells only with the piezoelectric 552 stimulation. Instead, the piezo-stimulation approach, when combined with sub-toxic TMZ 553 treatment, was able to significantly increase the percentage of apoptotic cells of about 25% and 554 to further reduce the proliferation rate of the cells with respect to the piezo-stimulation alone. 555 These results demonstrated as the nanoparticle-assisted remote piezoelectric stimulation 556 increases the sensitivity of glioblastoma cells to TMZ treatment. The synergic attack (chemical, 557 thanks to the chemotherapy drug, and physical, thanks to the remote electric stimulation) 558 remarkably reduced the cell number and the metabolic activity of glioblastoma cultures. The 559 remote piezo-stimulation has the potential to improve the therapeutic success by overcoming the 560 main obstacles for brain tumor treatment indicated in the Introduction, and will be tested in more 561 complex *in vivo* models and in preclinical studies. Particularly intriguing is the future perspective 562 to target also small microscopic foci of the GBM, that are the main cause of the recurrence of the 563 disease. A further point worth of investigation will be the analysis of the effects of nanoparticle 564 size / morphology on anticancer effects; indeed, the size / shape also affect the values of 565 piezoelectric and dielectric susceptibility coefficients,⁶⁰ thus not allowing to easily and 566 independently control the nanomaterial morphology and its piezoelectric behavior. 567 Summarizing, the main novelties of this research consist in the preparation of piezoelectric 568 nanoceramics able to cross a BBB model, to target glioblastoma cells, and to provide remote 569 electric stimulations for increasing GBM sensitivity to TMZ-based chemotherapy; on the other 570 hand, it is also necessary to underline the limits characterizing the present work, where *in vitro*

571 models of BBB and GBM were adopted, thus highlighting once more the needing for future *in*572 *vivo* experiments.

573 CONCLUSIONS

574 We presented for the first time the preparation of functionalized piezoelectric BTNPs for BBB-575 crossing, active cancer cell targeting, imaging, and remote US-driven electric treatment. 576 Moreover, we demonstrated the versatility of this nanotechnological approach, that allows the 577 successful delivery of antiproliferative stimuli to glioblastoma cells. Furthermore, the chronic 578 piezoelectric stimulation, in synergic combination with a sub-toxic concentration of TMZ, 579 induced an increased sensitivity to chemotherapy treatment and remarkable anticancer effects. 580 All together, these findings open new interesting perspectives in nanomedicine, with a 581 potential positive impact for the remote therapy of brain cancer and neurodegenerative 582 conditions. Future works will be focused on investigating the efficacy of nanoparticle-assisted 583 piezo-stimulation in xenograft models, in order to explore the realistic translation of these 584 nanomaterials in the future clinical practice. The possibility to fabricate piezoelectric BTNPs 585 with different size and higher piezoelectric coefficient by maintaining the same level of 586 biocompatibility will be assessed, and the effects of nanoparticle morphology on BBB crossing 587 and on piezo-stimulation efficiency will be evaluated. Moreover, the anticancer performances of 588 remote piezo-stimulation approach will be tested in combination with TMZ for the treatment of 589 TMZ-resistant glioblastoma cells, analyzing the molecular mechanisms at the base of TMZ 590 resistance and sensitivity. Finally, the combination of piezo-stimulation with different anticancer 591 drugs, radiotherapy and hyperthermia is envisaged in order to develop an efficient anticancer 592 protocol for pre-clinical studies.

593

594 AUTHOR STATEMENT OF CONTRIBUTIONS


595 A.M. performed the nanomaterial functionalization, the piezoelectric stimulation experiments

and the Ca^{2+} imaging and contributed to write the manuscript. E.A. carried out the tests

- 597 concerning the BBB crossing, and performed immunochemistry and statistical analysis. S.M.
- 598 performed viability studies and CLSM imaging. C.T. carried out nanomaterial characterization
- 599 (analysis of nanoparticle size, stability and BCA assay to evaluate the efficiency of nanomaterial
- 600 functionalization). M.B. developed and characterized the BBB model (TEER analysis, ZO-1
- 601 expression and Coomassie® Brilliant Blue Staining). V.C. performed TEM analysis. F.S.P. and
- 602 R.C. supervised the SHG acquisition. R.C. and M.M. built the SHG setup. M.M. and G.d.V.
- 603 performed the SHG acquisition and analyzed SHG data. G.C. supervised and planned the whole
- 604 work and contributed to write the manuscript. All authors have given approval to the final
- 605 version of the manuscript.

606 ACKNOWLEDGEMENTS

- 607 This work has received funding from the European Research Council (ERC) under the European
- 608 Union's Horizon 2020 research and innovation program (grant agreement N°709613, SLaMM).



- 610 Figure 1. Experimental scheme of a) BTNP functionalization with antibody against transferrin
- 611 receptor (TfR), b) nanoparticle crossing through a static 2D model of the BBB (nuclei in blue,
- 612 cell membranes in green and AbBTNPs in red), and c) chronic piezoelectric stimulation of
- 613 glioblastoma cells.






Figure 2. Analysis of BTNPs and AbBTNPs interaction with bEnd.3 cells and assessment of the
 BBB model crossing. a) SEM imaging and EDX analysis of BTNPs associated to the plasma

- 617 membranes of bEnd.3 cells (Ba in green and Ti in red). b) TEM image highlighting a higher
- amount of AbBTNPs associated to plasma membranes and up-taken by bEnd.3 cells with respect
- 619 to the non-functionalized BTNPs. c) CLSM of immunofluorescence staining of bEnd.3 cells
- against the ZO-1 marker after 72 h of BTNP / ABTNP treatment (nuclei in blue, f-actin in red,
- 621 ZO-1 in green and nanoparticles in white). d) CLSM imaging of bEnd.3 plasma membranes (in
- green), nanoparticles (in red) and nuclei (in blue), after 72 h of nanoparticle treatment. e-f)
- Histograms reporting intracellular and cell membrane areas (%) co-localizing with BTNPs /
- 624 AbBTNPs after 24 and 72 h of nanoparticle incubation, respectively. g) Concentrations of
- 625 BTNPs / AbBTNPs measured in the abluminal compartment after BBB crossing at different time
- 626 points (4, 24 and 72 h). * p < 0.05.





- 629 with 100 μg/ml BTNPs or AbBTNPs. a) CLSM imaging (plasma membranes in green,
- 630 nanoparticles in red and nuclei in blue), b) histogram of nanoparticle localization, and c) SHG
- 631 signal from nanoparticles (in red) overlaid on the outlines of the cells generated from the CARS
- 632 images. d-e) CLSM analysis of U-87 cells exposed to nanoparticles after BBB model crossing, d)
- 633 representative CLSM images of U-87 cells cultured in the abluminal compartment after 72 h of
- 634 BTNP or AbBTNP treatment in the luminal compartment; e) quantitative analysis of experiment
- 635 depicted in d). * p < 0.05.





Figure 4. Inhibitory effects of chronic piezoelectric stimulation on U-87 proliferation by testing different AbBTNP concentrations (100 μ g/ml and of 10 μ g/ml, the latter corresponding to the concentration of nanoparticles crossing the BBB model after a 72 h treatment). a) CLSM analysis of Ki-67 proliferation marker on control cultures, AbBTNPs-treated cells, US-stimulated cells, and on AbBTNPs+US treated cultures. b) Histogram reporting Ki-67⁺ nuclei (%). c) Timelapse Ca²⁺ imaging in response to plain US and to AbBTNPs+US (10 μ g/ml). Images at the top

show F/F_0 signal of cells after 5 min of US (top left) and AbBTNP+US (top right) stimulations.

643 At the bottom, the graph reports F/F_0 traces of cultures stimulated with US (in red) and with

644 US+AbBTNP (in black). * p < 0.05.



645 Figure 5. Nanoparticle-assisted piezoelectric stimulation (AbBTNPs+US) improves anticancer efficacy of temozolomide (TMZ). a) WST-1 assay on U-87 cells incubated for 24 h and 72 h with 646 647 different concentrations of drug (0-400 µg/ml; data are normalized and expressed as percentage 648 of WST-1 absorbance values measured at 24 h on control cultures). b) WST-1 assay respectively 649 performed on control cultures, cultures incubated with 10 µg/ml AbBTNPs, cultures incubated with 50 µg/ml TMZ, cultures incubated with 50 µg/ml TMZ and 10 µg/ml AbBTNPs, cultures 650 651 chronically stimulated with US, cultures stimulated with US in the presence of 10 µg/ml 652 AbBTNPs, cultures stimulated with US in the presence of 50 µg/ml TMZ, and, finally, cultures

stimulated with US in the presence of 10 μ g/ml AbBTNPs and of 50 μ g/ml TMZ. c) CLSM

imaging of Ki-67 and p53 expression in the different experimental conditions. The histograms

reporting the Ki-67⁺ and p53⁺ nuclei are respectively showed in d) and e). * p < 0.05.

656 REFERENCES

- S. S. Kim, J. B. Harford, K.F. Pirollo, E. H. Chang, *Biochem. Biophys. Res. Commun.*, 2015, **468**, 485-489.
- (2) C. Adamson, O. O. Kanu, A. I. Mehta, C. Di, N. Lin, A. K. Mattox, D. D. Bigner, *Expert Opin. Invest. Drugs*, 2009, **18**, 1061-1083.
- L. Cucullo, G. Dini, K. L. Hallene, V. Fazio, E. V. Ilkanich, C. Igboechi, K. M. Kight, M. K. Agarwal, M. Garrity-Moses, D. Janigro, *Glia*, 2005, 51, 65–72.
- E. D. Kirson, Z. Gurvich, R. Schneiderman, E. Dekel, A. Itzhaki, Y. Wasserman, R. Schatzberger, Y. Palti, *Cancer Res.*, 2004, 64, 3288–3295.
- (5) D. Janigro, C. Perju, V. Fazio, K. Hallene, G. Dini, M. K. Agarwal, L. Cucullo, *BMC Cancer*, 2006, 6, 72.
- (6) R. Stupp, S. Taillibert, A. A. Kanner, S. Kesari, D. M. Steinberg, S. A. Toms, L. Taylor, P. F. Lieberman, A. Silvani, K. L. Fink, G. H. Barnett, J. J. Zhu, J. W. Henson, H. H. Engelhard, T. C. Chen, D. D. Tran, J. Sroubek, N. D. Tran, A. F. Hottinger, J. Landolfi, R. Desai, M. Caroli, Y. Kew, J. Honnorat, A. Idbaih, E. D. Kirson, U. Weinberg, Y. Palti, M. E. Hegi, Z. Ram, *JAMA*, 2015, **314**, 2535–2543.
- R. Stupp, S. Taillibert, A. Kanner, W. Read, D. M. Steinberg, B. Lhermitte, S. Toms, A. Idbaih, M. S. Ahluwalia, K. Fink, F. Di Meco, F. Lieberman, J- Zhu, G. Stragliotto, D. D. Tran, S. Brem, A. F. Hottinger, E. D. Kirson, G. Lavy-Shahaf, U. Weinberg, C- Kim, S-Paek, G. Nicholas, J. Burna, H. Hirte, M. Weller, Y. Palti, M. E. Hegi, Z. Ram, *JAMA*, 2017, **318**, 2306-2316.
- (8) G. G. Genchi, A. Marino, A. Grillone, I. Pezzini, G. Ciofani, *Heathcare Mater.*, 2017, 6, 1700002.
- (9) A. Sneider, D. VanDyke, S. Paliwal, P. Rai, *Nanotheranostics*, 2017, 1, 1-22.

- G. Ciofani, S. Danti, D. D'Alessandro, L. Ricotti, S. Moscato, G. Bertoni, A. Falqui, S. Berrettini, M. Petrini, V. Mattoli, A. Menciassi, *ACS Nano*, 2010, 4, 6267–6277.
- A. Marino, S. Arai, Y. Hou, E. Sinibaldi, M. Pellegrino, Y.-T Chang, B. Mazzolai, V.
 Mattoli, M. Suzuki, G. Ciofani, *ACS Nano*, 2015, 9, 7678–7689.
- (12) A. Marino, G. G. Genchi, V. Mattoli, G. Ciofani, Nanotoday, 2017, 14, 10-13.
- (13) A. Marino, G. G. Genchi, E. Sinibaldi, G. Ciofani, ACS Appl. Mater. Interfaces, 2017, 9, 17663–17680.
- (14) X. Wang, J. Liu, J. Song, Z. L. Wang, *Nano Lett.*, 2007, 7, 2475–2479.
- (15) Y. Zhao, Q. Liao, G. Zhang, Z. Zhang, Q. Liang, X. Liao, Y. Zhang, *Nano Energy*, 2015, 11, 719–727.
- (16) X. Wang, J. Song, J. Liu, Z. L. Wang, Science, 2007, 316, 102–105.
- (17) C. A. Rojas Cifuentes, M. Tedesco, P. Massobrio, A. Marino, G. Ciofani, S. Martinoia, R.
 Raiteri, J. Neural Eng., 2018, 15, 036016.
- (18) A. Marino, M. Battaglini, D. De Pasquale, A. Degl'Innocenti, G. Ciofani, *Sci. Rep.*, 2018, 8, 6257.
- (19) M. Pinto, M. Arce, B. Yameen, C. Vilos, *Nanomedicine (Lond).*, 2017, **12**, 59-72.
- (20) N. Bertrand, J. Wu, X. Xu, N. Kamaly, O. C. Farokhzad, *Adv. Drug Deliv. Rev.*, 2014, 66, 2-25.
- (21) M. I. Alam, S. Beg, A. Samad, S. Baboota, K. Kohli, J. Ali, A. Ahuja, M. Akbar, *Eur. J. Pharm. Sci.*, 2010, **40**, 385-403.
- J. Chang, A. Paillard, C. Passirani, M. Morille, J- Benoit, D. Betbeder, E. Garcion, *Pharm. Res.*, 2012, **29**, 1495-505.
- (23) Y. Cui, Q. Xu, P. K. Chow, D. Wang, C. H. Wang, Biomaterials, 2013, 34, 8511-8520.

- (24) T. Kang, M. Jiang, D. Jiang, X. Feng, J. Yao, Q. Song, H. Chen, X. Gao, J. Chen, *Mol. Pharm.*, 2015, **12**, 2947-2961.
- (25) Z. Pang, W. Lu, H. Gao, K. Hu, J. Chen, C. Zhang, X. Gao, X. Jiang, C. Zhu, J. Control. Release, 2008, 128, 120-127.
- (26) H. Wei, H. Wang, Y. Xia, D. Cui, Y. Shi, M. Dong, C. Liu, T. Ding, J. Zhang, Y. Ma, N. Wang, Z. Wang, Y. Sun, R. Wei, Z. Guo, *J. Mater. Chem. C*, 2018, doi: 10.1039/C8TC04515A.
- (27) G. G. Genchi, A. Marino, A. Rocca, V. Mattoli, G. Ciofani, *Nanotechnology*, 2016, 27, 232001.
- (28) Z. Deng, Y. Dai, W. Chen, X. Pei, J. Liao, J. Nanoscale Res. Lett., 2010, 5, 1217-1221.
- (29) C- Hsieh, R. Grange, Y. Pu, D. Psaltis, *Biomaterials*, 2010, **31**, 2272-2277.
- (30) J. Čulić-Viskota, W. P. Dempsey, S. E. Fraser, P. Pantazis, *Nat. Protoc.*, 2012, 7, 1618-1633.
- (31) A. Marino, J. Barsotti, G. de Vito, C. Filippeschi, B. Mazzolai, V. Piazza, M. Labardi, V. Mattoli, G. Ciofani, ACS Appl. Mater. Interfaces, 2015, 7, 25574–25579.
- (32) Z. Sun, L. Zhang, F. Dang, Y. Liu, Z. Fei, Q. Shao, H. Lin, J. Guo, L. Xiang, N. Yerrad, Z. Guo, *CrystEngComm*, 2017, **19**, 3288-3298.
- (33) L. Zhang, W. Yu, C. Han, J. Guo, Q. Zhang, H. Xie, Q. Shao, Z. Sun, Z. Guo, J. *Electrochem. Soc.*, 2017, **164**, H651-H656.
- (34) L. Zhang, M. Qin, W. Yu, Q. Zhang, H. Xie, Z. Sun, Q. Shao, X. Guo, L. Hao, Y. Zheng,
 Z. Guo, J. Electrochem. Soc., 2017, 164, H1086-H1090.
- (35) B. Song, T. Wang, H. Sun, Q. Shao, J. Zhao, K. Song, L. Hao, L. Wang, Z. Guo, *Dalton Trans.*, 2017, 46, 15769-15777.

- (36) C. Tapeinos, A. Marino, M. Battaglini, S. Migliorin, R. Brescia, A. Scarpellini, C. De Julián Fernández, M. Prato, F. Drago, G. Ciofani, *Nanoscale*, 2018, doi: 10.1039/c8nr05520c.
- (37) Y. He, Y. Yao, S. E. Tsirka, Y. Cao, *Stroke*, 2014, 45, 2514-2526.(38) M. J. Clark, N. Homer, B. D. O'Connor, Z. Chen, A. Eskin, H. Lee, B. Merriman, S. F. Nelson, *PLoS Genet.*, 2010, 29; 6, e1000832.
- (39) A. Marino, S. Arai, Y. Hou, A. Degl'Innocenti, V. Cappello, B. Mazzolai, Y.-T. Chang, V. Mattoli, M. Suzuki, G. Ciofani, ACS Nano, 2017, 11, 2494–2508.
- (40) N. Emelianova, Eur. Phys. J. Appl. Phys., 2015, 69, 10401.
- (41) F. Chemat, M, A. Vian, G. Cravotto, Int. J. Mol. Sci., 2012, 13, 8615-8627.
- (42) F. Mallamace, C. Corsaro, D. Mallamace, S. Vasi, C. Vasi, G. Dugo, *Comput Struct Biotechnol J.*, 2014, 15, 33-7.
- (43) J. Kong, S. Yu, Acta Biochim. Biophys. Sin., 2007, 39, 549–559.
- (44) S. Bhattacharjee, J. Control. Release, 2016, 235, 337-351.
- (45) C. Hu, Z. Li, Y. Wang, J. Gao, K. Dai, G. Zheng, C. Liu, C. Shen, H. Song, Z, Guo, J. Mater. Chem. C, 2017, 5, 2318-2328.
- (46) Y. Li, B. Zhou, G. Zheng, X. Liu, T. Li, C. Yan, C. Cheng, K. Dai, C. Liu, C. Shena, Z. Guo, J. Mater. Chem. C, 2018, 6, 2258-2269.
- (47) A. Marino, M. Battaglini, I. Pezzini, G. Ciofani, Smart Inorganic Nanoparticles for Wireless Cell Stimulation. In "Smart Nanoparticles for Biomedicine", pp. 201-218, edited by Ciofani G. (Elsevier, UK, 2016).
- (48) A. Marino, S. Arai, Y. Hou, M. Pellegrino, B. Mazzolai, V. Mattoli, M. Suzuki, G. Ciofani, Assessment of the effects of a wireless neural stimulation mediated by piezoelectric

nanoparticles. In "Use of Nanoparticles in Neuroscience", pp. 109-120, edited by Santamaria F., Peralta X.G. (Humana Press, 2018).

- (49) G. G. Genchi, A. Rocca, A. Grillone, A. Marino, G. Ciofani, Boron nitride nanotubes in nanomedicine: Historical and future perspectives. In "Boron Nitride Nanotubes in Nanomedicine", pp. 201-218, edited by Ciofani G., Mattoli V. (Elsevier, UK, 2016).
- (50) S. Wohlfart, S. Gelperina, J. Kreuter, J. Control. Release, 2012, 161, 264–273.
- (51) F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D. A. Berk, V. P. Torchilin, R. K. Jain, *Cancer Res.*, 1995, **55**, 3752-3756.
- (52) S. K. Hobbs, W. L. Monsky, F. Yuan, W. G. Roberts, L. Griffith, V. P. Torchilin, R. K. Jain, *Proc. Natl. Acad. Sci. USA*, 1998, **95**, 4607-4612.
- (53) C. Saraiva, C. Praça, R. Ferreira, T. Santos, L. Ferreira, L. Bernardino, J. Control. Release, 2016, 235, 34-47.
- (54) N. Bien-Ly, Y. J. Yu, D. Bumbaca, J. Elstrott, C. A. Boswell, Y. Zhang, W. Luk, Y. Lu, M. S. Dennis, R. M. Weimer, I. Chung, J. Ryan, R. J. Watts, *J. Exp. Med.*, 2014, 211, 233–244.
- (55) T. R. Daniels, T. Delgado, J. A. Rodriguez, G. Helguera, M. L. Penichet, *Clin Immunol.*, 2006, **121**, 144-258.
- (56) D. L. Schonberg, T. E. Miller, Q. Wu, W. A. Flavahan, N. K. Das, J. S. Hale, C. G. Hubert,
 S. C. Mack, A. M. Jarrar, R. T. Karl, A. M. Rosager, A. M. Nixon, P. J. Tesar, P. Hamerlik,
 B. W. Kristensen, C. Horbinski, J. R. Connor, P. L. Fox, J. D. Lathia, J. N. Rich, *Cancer Cell*, 2015, 28, 441–455.
- (57) T. Kang, M. Jiang, D. Jiang, X. Feng, J. Yao, Q. Song, H. Chen, X. Gao, J. Chen, *Mol. Pharm.*, 2015, **12**, 2947-2961.

- (58) K. B. Johnsen, M. Bak, P. J. Kempen, F. Melander, A. Burkhart, M. S. Thomsen, M. S. Nielsen, T. Moos, T. L. Andresen, *Theranostics*, 2018, 8, 3416-3436.
- K. B. Johnsen, A. Burkhart, F. Melander, P. J. Kempen, J. B. Vejlebo, P. Siupka, M. S. Nielsen, T. L. Andresen, T. Moos, *Sci. Rep.*, 2017, 7, 10396.
- (60) P. Zheng, J. L. Zhang, Y. Q. Tan, C. L. Wang, Acta Mater., 60, 5022-5030.

658 Graphical abstract

